JP2016117766A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016117766A5 JP2016117766A5 JP2016055140A JP2016055140A JP2016117766A5 JP 2016117766 A5 JP2016117766 A5 JP 2016117766A5 JP 2016055140 A JP2016055140 A JP 2016055140A JP 2016055140 A JP2016055140 A JP 2016055140A JP 2016117766 A5 JP2016117766 A5 JP 2016117766A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- light
- molecule
- mutant
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 32
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 239000003795 chemical substances by application Substances 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 101000830594 Homo sapiens Tumor necrosis factor ligand superfamily member 14 Proteins 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 102000051198 human TNFSF14 Human genes 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102000005962 receptors Human genes 0.000 claims 5
- 108020003175 receptors Proteins 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 206010027476 Metastases Diseases 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000009401 metastasis Effects 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 2
- -1 HERB Proteins 0.000 claims 2
- 241001529936 Murinae Species 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 102000012883 Tumor Necrosis Factor Ligand Superfamily Member 14 Human genes 0.000 claims 2
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 claims 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102000012220 Member 14 Tumor Necrosis Factor Receptors Human genes 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576222P | 2011-12-15 | 2011-12-15 | |
| US61/576,222 | 2011-12-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014547350A Division JP2015501839A (ja) | 2011-12-15 | 2012-12-11 | 受容体に対する親和性が増大した変異型ｌｉｇｈｔ分子を使用する癌療法のための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016117766A JP2016117766A (ja) | 2016-06-30 |
| JP2016117766A5 true JP2016117766A5 (enExample) | 2017-02-16 |
| JP6113883B2 JP6113883B2 (ja) | 2017-04-12 |
Family
ID=47436247
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014547350A Pending JP2015501839A (ja) | 2011-12-15 | 2012-12-11 | 受容体に対する親和性が増大した変異型ｌｉｇｈｔ分子を使用する癌療法のための方法および組成物 |
| JP2016055140A Expired - Fee Related JP6113883B2 (ja) | 2011-12-15 | 2016-03-18 | 受容体に対する親和性が増大した変異型ｌｉｇｈｔ分子を使用する癌療法のための方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014547350A Pending JP2015501839A (ja) | 2011-12-15 | 2012-12-11 | 受容体に対する親和性が増大した変異型ｌｉｇｈｔ分子を使用する癌療法のための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9493532B2 (enExample) |
| EP (1) | EP2790730B1 (enExample) |
| JP (2) | JP2015501839A (enExample) |
| CN (1) | CN104284680A (enExample) |
| AU (1) | AU2012352454A1 (enExample) |
| CA (1) | CA2858876A1 (enExample) |
| WO (1) | WO2013090293A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2790730B1 (en) | 2011-12-15 | 2019-01-23 | The University of Chicago | Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors |
| WO2014157692A1 (ja) | 2013-03-29 | 2014-10-02 | 大日本住友製薬株式会社 | Ｗｔ１抗原ペプチドコンジュゲートワクチン |
| US11000603B2 (en) | 2015-04-14 | 2021-05-11 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
| EP3299028B1 (en) * | 2015-05-20 | 2024-10-30 | Sumitomo Pharma Co., Ltd. | Combination of wt1 antigen peptide, immunomodulator and wt1 helper peptide |
| CN108348590A (zh) * | 2015-09-18 | 2018-07-31 | 综合医院公司以麻省总医院名义经营 | 用于治疗癌症的具有抗趋除特性的组合物 |
| EP4245775A3 (en) * | 2016-04-29 | 2023-11-15 | Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
| WO2017219974A1 (zh) | 2016-06-22 | 2017-12-28 | 本康生物制药（深圳）有限公司 | 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用 |
| CN106701825A (zh) * | 2016-11-17 | 2017-05-24 | 中国科学院生物物理研究所 | 腺病毒疫苗Ad‑LIGHT‑HBsAg及其用于治疗慢性乙肝的用途 |
| EP3549957A4 (en) | 2016-11-30 | 2020-08-05 | Sumitomo Dainippon Pharma Co., Ltd. | AUXILIARY PEPTIDE WT1, AND COMBINATION OF DUDIT PEPTIDE AND CONJUGATE PEPTIDE ANTIGENIC FOR CANCER |
| CN110869032B (zh) * | 2017-02-17 | 2024-08-23 | 匹兹堡大学联邦系统高等教育 | 脂肪相关淋巴簇作为多种组织的移植、组织再生、器官发生和功能的位点 |
| KR102371420B1 (ko) * | 2017-06-27 | 2022-03-08 | (주)아모레퍼시픽 | Tnfsf14 단백질을 포함하는 미백용 조성물 |
| EP3846829A4 (en) * | 2018-09-05 | 2022-09-14 | Arizona Board of Regents on behalf of Arizona State University | ONCOLYTIC VIRUS PLATFORM FOR THE TREATMENT OF HEMATOLOGICAL CANCER |
| CN116426483B (zh) * | 2021-12-30 | 2024-02-23 | 南京紫珑生物科技有限公司 | Cd258蛋白在免疫治疗中的应用 |
| KR20250022126A (ko) * | 2022-06-08 | 2025-02-14 | 길리애드 사이언시즈, 인코포레이티드 | Light 뮤테인 및 그 용도 |
| CN116083435A (zh) * | 2022-11-04 | 2023-05-09 | 吉林大学 | 以人源light截短型突变蛋白为基础的抗肿瘤的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5874560A (en) | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| KR20000049096A (ko) | 1996-10-11 | 2000-07-25 | 린다 에스. 스티븐슨 | 혼합 림프구와 조합된 종양세포를 사용하는 암 면역요법 |
| US6048551A (en) | 1997-03-27 | 2000-04-11 | Hilfinger; John M. | Microsphere encapsulation of gene transfer vectors |
| WO2001079496A2 (en) | 2000-03-13 | 2001-10-25 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
| US7811983B2 (en) * | 2003-06-11 | 2010-10-12 | The University Of Chicago | Increased T-cell tumor infiltration and eradication of metastases by mutant light |
| CA2529058A1 (en) * | 2003-06-11 | 2005-01-13 | The University Of Chicago | Increased t-cell tumor infiltration by mutant light |
| EP2160200B1 (en) * | 2007-05-14 | 2013-07-10 | The University of Chicago | Antibody-LIGHT fusion products as cancer therapeutics |
| AU2009308707A1 (en) * | 2008-10-31 | 2010-05-06 | Biogen Idec Ma Inc. | LIGHT targeting molecules and uses thereof |
| EP2790730B1 (en) | 2011-12-15 | 2019-01-23 | The University of Chicago | Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors |
-
2012
- 2012-12-11 EP EP12806814.5A patent/EP2790730B1/en active Active
- 2012-12-11 CN CN201280069840.2A patent/CN104284680A/zh active Pending
- 2012-12-11 WO PCT/US2012/069013 patent/WO2013090293A1/en not_active Ceased
- 2012-12-11 AU AU2012352454A patent/AU2012352454A1/en not_active Abandoned
- 2012-12-11 US US14/363,243 patent/US9493532B2/en active Active
- 2012-12-11 JP JP2014547350A patent/JP2015501839A/ja active Pending
- 2012-12-11 CA CA2858876A patent/CA2858876A1/en not_active Abandoned
-
2016
- 2016-03-18 JP JP2016055140A patent/JP6113883B2/ja not_active Expired - Fee Related
- 2016-11-02 US US15/341,678 patent/US10167328B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016117766A5 (enExample) | ||
| WO2013090293A4 (en) | Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors | |
| CN107849148B (zh) | 三特异性结合蛋白质及使用方法 | |
| AU2014377106B2 (en) | IL-15 heterodimeric protein and uses thereof | |
| JP2017140051A5 (enExample) | ||
| RU2486204C2 (ru) | Антитела против сd26 и способы их применения | |
| JP2015532102A5 (enExample) | ||
| JPWO2019246004A5 (enExample) | ||
| CN113330034A (zh) | 针对B7-H3的IgV结构域的单克隆抗体及其用途 | |
| JP2017506217A5 (enExample) | ||
| JP2007532139A5 (enExample) | ||
| JP2023123649A5 (enExample) | ||
| JP2016156828A5 (enExample) | ||
| JP2019531697A5 (enExample) | ||
| CN118251414A (zh) | 延长释放免疫细胞衔接蛋白和治疗方法 | |
| JP2015530359A5 (enExample) | ||
| CA2973538C (en) | Antibody-urease conjugates for therapeutic purposes | |
| WO2017107914A1 (zh) | 一种药物设计方法和获得的药物及其应用 | |
| EP4277707A1 (en) | Interferon prodrugs and methods of making and using the same | |
| Fan et al. | AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells | |
| JPWO2020264200A5 (enExample) | ||
| JPWO2020172528A5 (enExample) | ||
| JPWO2020214690A5 (enExample) | ||
| WO2023031644A1 (en) | Anti-fibroblast activation protein (fap) single domain antibodies and uses thereof | |
| WO2014166029A1 (zh) | 针对表皮生长因子受体的抗体 |